News Seismic shakes up $121m for AI-designed immunology drugs Seismic Therapeutics has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.
Patients On patient-centric treatment decisions and the value of quan... Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, discusses the pressing need for quantitative methodologies.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face